Cancel

Myeloma Masters: The Ultimate Myeloma Patient Care Quiz Show

Multiple myeloma management has advanced significantly in recent years, providing new hope for myeloma patients but creating new challenges for health care providers. Using an engaging and entertaining game show format (think Who Wants to Be a Millionaire), this activity tests players’ knowledge of current and emerging myeloma patient care best practices. Along the way—using a range of multimedia prompts and hints—the game presents information on several fast-evolving areas of myeloma ca...
Purdue University School of Nursing

Myeloma Masters: The Ultimate Myeloma Patient Care Quiz Show

Target Audience This activity has been designed to meet the educational needs of oncology nurses, advanced oncology certified nurse practitioners, and other health care providers involved in the care of patients with multiple myeloma. Program Overview Multiple myeloma management has advanced significantly in recent years, providing new hope for myeloma patients but creating new challenges for health care providers. Using an engaging and entertaining game show format (think Who Wants t...
Relias LLC

AL Amyloidosis: A Rare Blood Disorder with Multi-Organ Complications

Target Audience The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, medical oncologists, hematologic oncologists, pathologists, radiologic oncologists, surgical oncologists, primary care providers, internists, oncology nurses, nurse navigators, nurse practitioners, physician assistants, and pharmacists. Statement of Need/Program Overview The wide range of symptoms for amyloidosis that overlap with other conditions often...
Global Education Group and PlatformQ Health Education, LLC.

What’s My (Next) Line? Treating Relapsed/Refractory Multiple Myeloma When Three Prior Treatment Lines Fail

Although outcomes for patients with multiple myeloma (MM) have improved with targeted agents and combination therapies, most MM patients inevitably relapse. Furthermore, the duration and quality of response to treatment deteriorates following each subsequent line of therapy, and the risk of another relapse rises. The emergence of B-cell maturation antigen (BCMA)-targeting antibody-drug conjugates, bispecific antibodies, CAR T-cell therapy, and novel small-molecule agents has offered innovative...
Purdue University College of Pharmacy

Applying the Latest Clinical Data in Multiple Myeloma Patient Care in the Community Setting

In recent years, there have been significant advances in multiple myeloma (MM) management, including approvals of new drugs and treatment combinations. For some patients, however, the benefits of these advances remain elusive: disparities in MM care among Black patients, who are more likely to be treated in the community setting, persist across the spectrum of MM care. Though evidence-based MM treatment guidelines and consensus statements are available, ongoing studies continue to provide i...
Penn State College of Medicine

Putting the CAR(T) Before the Horse: Practicalities of T Cell-Activating Therapies in Multiple Myeloma

ACTIVITY DESCRIPTION Patients with multiple myeloma that is refractory to multiple classes of therapeutics can be particularly difficult to treat. Fortunately, the treatment landscape is expanding, and a range of new therapies for patients with multiply relapsed or refractory multiple myeloma (RRMM) is rapidly emerging. In particular, chimeric antigen receptor (CAR) T-cell therapy is a powerful new immunotherapy that has revolutionized cancer treatment and has been approved for patients with ...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Ace the Case: Multiple Myeloma Presentation in the Community Setting

Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners. This educational program is designed to meet the educational needs of the members of the care team (oncologists, h...
American Academy of CME

Ace the Case: Treating First Multiple Myeloma Relapse in the Community Setting

Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners. This educational program is designed to meet the educational needs of the members of the care team (oncologists, h...
American Academy of CME

Ace the Case: R/R MM After 4 Lines of Therapy: What are the options?

Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners. This educational program is designed to meet the educational needs of the members of the care team (oncologists, h...
American Academy of CME

Oncology Data Advisor™: Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma

STATEMENT OF NEED Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification (Kumar et al, 2022). Clinicians need to continually update their working knowledge of emerging data and consensus recommendations that can rationally inform clinical decision making. In Modul...
i3 Health

On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma

Program Overview On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma aims to provide clinical data regarding current and emerging therapeutic BCMA-directed treatment strategies via a panel of experts treating patients with multiple myeloma. Target Audience The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and ot...
Relias LLC

Nursing Management of Bone Health in Patients with Cancer

Once it has metastasized to the skeletal system, cancer often negatively affects bone health, leading to pain, fractures, hypercalcemia, and nerve compression. This online activity reviews interventions to reduce morbodity and mortality of bone complications in patients with cancer. STATEMENT OF NEED Advanced-stage cancers, including lung, breast, prostate, and multiple myeloma, can have a detrimental effect on bone health (Coleman, Croucher et al, 2020). Once cancer spreads to the skel...
i3 Health

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map